Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test could spot dangerous pregnancy condition early

NCT ID NCT06716242

Diagnosis Sponsor: iPremom Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new blood test called the MaiRa Preeclampsia Test to see if it can accurately predict preeclampsia early in pregnancy. Preeclampsia is a serious condition that can harm both mother and baby. The test looks at genetic material in the mother's blood to identify women at risk, so doctors can take steps to prevent complications. About 7,500 pregnant women will participate to confirm the test works reliably.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 7,473 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Pregnant patients aged 18 years or older, recruited between 9 and 14 weeks' gestation during routine obstetrical follow-ups at referral hospitals.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent approved by the Ethics Committee. * Women ≥18 years of age at consent. * Single gestation pregnancies with first sample collection (T1) possible between 9 and 14 weeks' gestation. Exclusion Criteria: * Active neoplasm. * History of organ or bone marrow transplantation. * Maternal transfusion within 8 weeks before sample collection. * Evidence of early pregnancy loss at consent. * Severe, uncontrolled infections. * Other investigator-assessed risks that could compromise participation or data quality.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Preeclampsia (PE) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

preeclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Preeclampsia (PE)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Clínico Universitario Virgen de la Arrixaca

    RECRUITING

    El Palmar, Murcia, 30120, Spain

  • Hospital Comarcal de Vinaròs

    RECRUITING

    Vinaròs, Castellón, 12500, Spain

  • Hospital General Universitario Dr. Balmis

    RECRUITING

    Alicante, Alicante, 03010, Spain

  • Hospital Universitario A Coruña

    RECRUITING

    A Coruña, La Coruña, 15006, Spain

  • Hospital Universitario Doctor Peset

    RECRUITING

    Valencia, Valencia, 46017, Spain

  • Hospital Universitario Puerta del Mar

    RECRUITING

    Cadiz, Cádiz, 11009, Spain

  • Hospital Universitario de Canarias

    RECRUITING

    San Cristóbal de La Laguna, Santa Cruz de Tenerife, 38320, Spain

  • Hospital Universitario de Torrejón

    RECRUITING

    Torrejón de Ardoz, Madrid, 28850, Spain

  • Hospital Universitario y Politécnico La Fe

    RECRUITING

    Valencia, Valencia, 46026, Spain

  • Hospital de Manises

    RECRUITING

    Manises, Valencia, 46940, Spain

  • Hospital de la Santa Creu i Sant Pau

    RECRUITING

    Barcelona, Barcelona, 08025, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.